Comparative Pharmacology
Head-to-head clinical analysis: LAMIVUDINE TENOFOVIR DISOPROXIL FUMARATE NEVIRAPINE versus LAMIVUDINE ZIDOVUDINE TABS 150MG 300MG CO PACKAGED WITH NEVIRAPINE TABS 200MG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAMIVUDINE TENOFOVIR DISOPROXIL FUMARATE NEVIRAPINE versus LAMIVUDINE ZIDOVUDINE TABS 150MG 300MG CO PACKAGED WITH NEVIRAPINE TABS 200MG.
LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE; NEVIRAPINE vs LAMIVUDINE, ZIDOVUDINE TABS 150MG/300MG CO-PACKAGED WITH NEVIRAPINE TABS 200MG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits HIV-1 reverse transcriptase via DNA chain termination after intracellular phosphorylation to lamivudine triphosphate. Tenofovir disoproxil fumarate is a nucleotide reverse transcriptase inhibitor (NtRTI) that, after hydrolysis and phosphorylation, inhibits HIV-1 reverse transcriptase by competing with deoxyadenosine 5'-triphosphate and causing DNA chain termination. Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that directly binds to and inhibits HIV-1 reverse transcriptase, causing a conformational change and reducing enzyme activity.
Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits HIV reverse transcriptase via DNA chain termination after intracellular phosphorylation to lamivudine triphosphate. Zidovudine is also an NRTI that inhibits HIV reverse transcriptase after phosphorylation to zidovudine triphosphate. Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to reverse transcriptase, causing enzyme inhibition.
One tablet (300 mg lamivudine, 300 mg tenofovir disoproxil fumarate, 400 mg nevirapine) orally once daily. Nevirapine requires a 14-day lead-in dose of 200 mg once daily when initiating therapy.
One tablet of lamivudine/zidovudine (150 mg/300 mg) orally twice daily. One tablet of nevirapine (200 mg) orally once daily for 14 days, then one tablet twice daily thereafter.
None Documented
None Documented
Lamivudine: 5-7 hours in adults (extended to 20-30 hours in renal impairment). Tenofovir: 17-18 hours in adults (prolonged in renal impairment). Nevirapine: ~45 hours (single dose) to 25-30 hours (multiple doses due to autoinduction).
Lamivudine: 5-7 hours (terminal half-life); prolonged to ~10-15 hours in advanced HIV infection; increased with renal impairment. Zidovudine: 0.5-3 hours (mean ~1 hour); prolonged to ~1.5-3 hours in renal impairment; intracellular active metabolite zidovudine-triphosphate has half-life ~3-7 hours. Nevirapine: ~25-30 hours (single dose), ~40-60 hours with multiple dosing (autoinduction reduces to ~20-30 hours after 2-4 weeks).
Lamivudine: 70% renal (glomerular filtration and tubular secretion) as unchanged drug. Tenofovir: 70-80% renal (glomerular filtration and tubular secretion) as unchanged drug. Nevirapine: ~81% renal (metabolites, <5% unchanged), ~10% fecal.
Lamivudine: ~70% renal (glomerular filtration and active tubular secretion) as unchanged drug; ~30% metabolized to inactive metabolites (trans-sulfoxide) excreted renally. Zidovudine: ~75% renal (metabolite zidovudine-glucuronide) and ~20% unchanged; ~5% fecal. Nevirapine: ~80% renal (metabolites, mainly 2-hydroxy- and 3-hydroxy-nevirapine glucuronides), ~10% fecal, <5% unchanged.
Category A/B
Category A/B
NRTI
NRTI